
CORRIGENDUM

RNA-based therapies

Irena Melnikova

Nature Reviews Drug Discovery **6**, 863–864 (2007) | doi:10.1038/nrd2443

The author wishes to clarify that in the development programme of RTP801i, the involvement of Silence Therapeutics was limited to licensing its RNAi technology to Quark Pharmaceuticals. In September 2006, Quark granted Pfizer an exclusive worldwide license to develop and commercialize RTP801i for both ophthalmic and non-ophthalmic indications.